Nyxoah to Participate in the Jefferies London Healthcare Conference
07 Novembre 2023 - 10:30PM
Nyxoah to Participate in the Jefferies London Healthcare Conference
Nyxoah to Participate in the Jefferies
London Healthcare Conference
Mont-Saint-Guibert, Belgium – November
7, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext
Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a
medical technology company focused on the development and
commercialization of innovative solutions to treat Obstructive
Sleep Apnea (OSA), today announced that the Company will
participate in the Jefferies London Healthcare Conference, which
takes place November 14 – 16, 2023 in London.
Olivier Taelman, Nyxoah’s Chief Executive
Officer, will deliver a corporate update on Wednesday, November 15,
2023, at 5:00pm GMT. A webcast of the presentation will be
available on the Events section of Nyxoah’s Investor Relations
website. The Company will also be available for 1x1 meetings with
institutional investors attending the event.
Nyxoah’s Investor Presentation can be accessed
on the Shareholder Information section of the Company’s Investor
Relations page.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Nyxoah completed two successful IPOs: on Euronext Brussels in
September 2020 and NASDAQ in July 2021. Following the positive
outcomes of the BETTER SLEEP study, Nyxoah received CE mark
approval for the expansion of its therapeutic indications to
Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company
is currently conducting the DREAM IDE pivotal study for FDA and
U.S. commercialization approval.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Contact:NyxoahDavid DeMartino,
Chief Strategy Officerdavid.demartino@nyxoah.com +1 310 310
1313
- ENGLISH_Nyxoah to Participate in the London Healthcare
Conference_FINAL
Grafico Azioni Nyxoah (EU:NYXH)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Nyxoah (EU:NYXH)
Storico
Da Mag 2023 a Mag 2024